Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Dosing completed in phase II study of Puricase for severe gout

Jan. 12, 2005

New phase IIb study for CS-917 in type 2 diabetes

Jan. 12, 2005

Phospholipase inhibitors prepared and tested at Lilly

Jan. 11, 2005

Alliance and LEO Pharma to enter Oxygent agreement for Europe and Canada

Jan. 11, 2005

PTP-1B inhibitors prepared and tested at Sankyo

Jan. 10, 2005

GLP-1 analogue decreases weight gain and food intake in rats

Jan. 10, 2005

Merck & Co. develops MB-243, a novel melanocortin receptor agonist

Jan. 5, 2005

Kinase inhibitors disclosed in Janssen patent

Jan. 5, 2005

Insmed completes SomatoKine NDA

Jan. 4, 2005

NDA submission for Seasonique extended-cycle oral contraceptive

Jan. 4, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.